MK-0476, montelukast sodium
DrugDuration of Treatment: 14 Days
NCT Number: NCT00394069
The purpose of this study is to look at the preliminary safety profile of an investigational drug in children 3 to 6 months of age with bronchiolitis.
Looking for future studies?
Notify Me3 month–6 month
All sexes
Interventional
Phase 2
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Duration of Treatment: 14 Days
Time frame: 14 days
Time frame: 24 hours
Organon and Co
Industry
A Randomized, 3-Period, Multiple-Dose, Multicenter Study to Evaluate the Safety, Tolerability, and Plasma Concentration Profile of Montelukast Administered Once Daily as Oral Granules in Children Aged 3 to 6 Months
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06932341
Bronchial Diseases, Bronchiolitis
St. Petersburg, Florida, United States
View Trial DetailsNCT06016244
Bronchial Diseases, Bronchial Hyperreactivity
Haarlem, North Holland, Netherlands
View Trial DetailsNCT02824744
Bronchial Diseases, Bronchiolitis
Montpellier, France
View Trial DetailsNCT03298217
Bronchial Diseases, Bronchiolitis
Montpellier, France
View Trial Details